anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND AND OBJECTIVE: In locally advanced cancer, bleeding is a common clinical presentation and radiotherapy (RT) provides a noninvasive, well-tolerated, cost-effective treatment. However, the choice for fractionation dose and schedule seem to merely depend on physician's preference rather than specific guidelines. We reviewed the available literature on palliative hemostatic RT for response rate (RR) and bleeding duration in relation with the given dose.
METHODS: The PubMed database was used to search for articles, which were assessed by predetermined inclusion and exclusion criteria. A total of 54 articles, published over the last 20 years until December 2023 were analyzed for dose and/or fractionation regimen and their relation to the RR.
KEY CONTENT AND FINDINGS: A variety of fractionation schedules are used for palliative symptom control, including hemostasis. Research focusing on hemostatic irradiation specifically and prospective studies are rare. Moreover, to our knowledge, there are no specific (prospective) studies ongoing. Both external beam radiotherapy (EBRT) and brachytherapy lead to bleeding control and daily or weekly hypofractionated irradiation is safe and effective for both high and low biological equivalent dose (BED) regimens. If feasible, based on patient condition, some studies favor higher BED regimens to obtain more durable tumor/higher bleeding response. Higher radiation dose for thoracic irradiation may be indicative for simultaneous presentation of obstruction and/or dysphagia. Brachytherapy may be used solely or in combination with EBRT or in the setting of re-irradiation. Short-course regimens are preferred in patients in with low performance index scores. For future studies, multivariate analysis, including BED, can be important to assess efficacy of different fractionation schedules for a variety of tumor etiologies.
CONCLUSIONS: Hemostatic RT, both by EBRT and brachytherapy, appears to be a safe and effective palliative treatment that clinically and statistically significantly reduces bleeding in cancer patients. The available literature is limited regarding prospective and uniform evaluation of hemostatic RT, including fractionation schedules. BED seems to be indicative for a better RR for specific indications. Current evidence suggests that treatment decisions should be tailored according to the patients' condition, tumor etiology and other clinical symptoms. More (prospective) research focusing on hemostasis is necessary to develop clear guidelines.
FIELD: biotechnology, immunology. SUBSTANCE: fraction-III obtained by spirituous Cohn's method is concentrated by ultrafiltration at pH value 3.5-5.0, then washed out with ethanol, final solution is concentrated and stabilizing agent is added. Then immunoglobulin content is brought about to 5% and pH value to 3.5-5.0. Sterilizing filtration is carried out and immunoglobulin hydrate envelopes are reduced before stabilizing agent addition. Reduction is carried out by method of molecular filtration at different sites of semipermeable membrane. The latter is an ultrafiltering membrane at interception limit less 100,000 Da by molecular mass or dialysis viscose envelopes. Anticomplementary activity of immunoglobulin preparation obtained by the indicated technology is less 10 of mg protein. Preparation is are active at intravenous administration. Preparation has ethanol-free immunoglobulin with reduced hydrate envelopes and stabilizing agent. EFFECT: improved method of preparing, increased activity. 2 cl, 2 dwg, 1 tbl, 2 ex
PURPOSE:A carcinostatic adjuvant, consisting of an extract essence selected from one of SHAKUYAKU KANZOTO (Paeoniae Radix and Glycyrrhizae Radix), BYAKKOKA NINJINTO (Anemarrhenae Rhizoma, Ginseng Radix, etc.) and JUZENTAIHOTO (Ginseng Radix and Astragali Radix) and capable of enhancing carcinostatic action of cisplatin and relieving side effect. CONSTITUTION:A carcinostatic adjuvant obtained by extracting SHAKUYAKU KANZOTO (Paeoniae Radix and Glycyrrhizae Radix), BYAKKOKA NINJINTO (Anemarrhenae Rhizoma, Ginseng Radix, etc.) or JUZENTAIHOTO (Ginseng Radix aand Astragali Radix) with a solvent, e.g. water, ethanol, etc., preferably providing a concentrated extract essence and further, as necessary, converting the essence into dried extract essence powder. The above-mentioned extract essence of the herb medicine will not exhibit individual carcinostatic action, but is capable of enhancing the carcinostatic action of cisplatin and inhibiting the increase in BUN value caused by the cisplatin and mitigating toxicity. This medicine is orally adminiastered for each administration of the cisplatin but is preferably continuously administered even during a period of suspended administration of the cisplatin.
PURPOSE:A dentifrice composition, having improved transparency retention at a low temperature, and containing polyethylene glycol of specific molecular weight. CONSTITUTION:A dentifirce composition containing a polyethylene glycol having an average molecular weight of 450 or less, preferably 200-400, in a transparent dentifrice composition containing an anion surfactant, e.g. sodium lauryl sulfate. An anion surfactant as a foaming agent added to a transparent dentifrice reduces the transparency due to the deposition thereof on storing for a long term at a low temperature, e.g. -5 deg.C in the winter season. The deposition of the surfactant can be prevented by adding the polyethylene glycol of specific molecular weight to the composition.
Several perinatal factors influence the intestinal microbiome of newborns during the first days of life, whether during delivery or even in utero. These factors may increase the risk of developing necrotizing enterocolitis (NEC) by causing dysbiosis linked to a NEC-associated microbiota, which may also be associated with other gastrointestinal problems. The objective of our study was to evaluate the potential risks associated with microbial shifts in newborns with gastrointestinal symptoms and identify the intestinal microbiota of neonates at risk for NEC.During the study period, 310 preterm and term newborns' first passed meconium occurring within 72 h of birth were collected, and the microbiome was analyzed. We identified the risk factors in the NEC/FI group. Regarding microbiota, we compared the bacterial abundance between the NEC/FI group at the phylum and genus levels and explored the differences in the microbial composition of the 1st stool samples. A total of 14.8% (n = 46) of the infants were diagnosed with NEC or FI. In univariate analysis, the mean gestational age and birth weight were significantly lower in the NEC/FI group (p < 0.001). Prolonged rupture of membranes (PROM) > 18 h, chorioamnionitis, and histology were significantly higher in the NEC/FI group (p < 0.001). Multivariate analysis showed that gestational age (GA), prolonged membrane rupture (> 18 h), and early onset sepsis were consistently associated with an increased risk of NEC/FI. Infants diagnosed with NEC/FI exhibited a significantly lower abundance of Actinobacteria at the phylum level than the control group (p < 0.001). At the genus level, a significantly lower abundance of Streptococcus and Bifidobacterium which belong to the Actinobacteria phylum, was observed in the NEC/FI group (p < 0.001). Furthermore, the NEC/FI had significantly lower alpha diversities (Shannon Index,3.39 vs. 3.12; P = 0.044, respectively). Our study revealed that newborns with lower diversity and dysbiosis in their initial gut microbiota had an increased risk of developing NEC, with microbiota differences appearing to be associated with NEC/FI. Dysbiosis could potentially serve as a predictive marker for NEC- or GI-related symptoms.
Hybrid immunity (vaccination + natural infection) to SARS-CoV-2 provides superior protection to re-infection. We performed immune profiling studies during breakthrough infections in mRNA-vaccinated hamsters to evaluate hybrid immunity induction. The mRNA vaccine, BNT162b2, was dosed to induce binding antibody titers against ancestral spike, but inefficient serum virus neutralization of ancestral SARS-CoV-2 or variants of concern (VoCs). Vaccination reduced morbidity and controlled lung virus titers for ancestral virus and Alpha but allowed breakthrough infections in Beta, Delta and Mu-challenged hamsters. Vaccination primed for T cell responses that were boosted by infection. Infection back-boosted neutralizing antibody responses against ancestral virus and VoCs. Hybrid immunity resulted in more cross-reactive sera, reflected by smaller antigenic cartography distances. Transcriptomics post-infection reflects both vaccination status and disease course and suggests a role for interstitial macrophages in vaccine-mediated protection. Therefore, protection by vaccination, even in the absence of high titers of neutralizing antibodies in the serum, correlates with recall of broadly reactive B- and T-cell responses.
This is a prospective, longitudinal, observational exploratory study. Ten subjects will be enrolled and will complete baseline and week 4 blood draws and symptom questionnaires at baseline, 1-, 2-, 3- and 4-weeks.
Patients who were enrolled in the open-label control group of Phase I and who have completed the 3-month follow-up will be permitted to enroll in Phase II. This Phase will start treatment after completion of Phase I and approval from the Data and Safety Monitoring Board (DSMB) to proceed with a single cohort that will receive a stable dose of the study drug (20 µg T3 orally twice daily for 5 days).
Deep venous thrombosis (DVT) and pulmonary embolism (PE) were observed in subjects receiving CIBINQO in the clinical trials for atopic dermatitis [see Adverse Reactions (6.1)].

Thrombosis, including DVT, PE, and arterial thrombosis have been reported in patients receiving JAK inhibitors used to treat inflammatory conditions. Many of these adverse reactions were serious and some resulted in death. 

In a large, randomized, postmarketing safety trial of another JAK inhibitor in RA subjects 50 years of age and older with at least one cardiovascular risk factor, higher rates of overall thrombosis, DVT, and PE were observed compared to those treated with TNF blockers. CIBINQO is not approved for use in RA.

Avoid CIBINQO in patients that may be at increased risk of thrombosis. If symptoms of thrombosis occur, discontinue CIBINQO and evaluate and treat patients appropriately.
The invention relates to the field of biological pharmacy, in particular to a polysaccharide-carrier protein conjugate, a preparation method and application thereof. In the polysaccharide-carrier protein conjugate, the carrier protein is a recombinant tetanus toxin C fragment (TTc) with an amino acid sequence shown in SEQ ID No. 1. The invention also relates to the use of the recombinant tetanus toxin C fragment. The polysaccharide-carrier protein conjugate of the invention can be used for preventing infectious diseases caused by bacteria corresponding to the capsular polysaccharide contained in the conjugate, and particularly can be used for preventing infectious diseases caused by haemophilus influenzae type b (Hib). The polysaccharide-carrier protein conjugate produced by using the recombinant TTc protein has higher yield, can obviously improve the immune response level of mice, and has better immune effect than tetanus toxoid carrier conjugate.
Background: Patients with SAIS are commonly referred to physical therapy. A common impairment among patients with SAIS is altered scapular movement, characterized by insufficient upward rotation and posterior tilt. These deficits are believed to decrease the subacromial space and diminish length -tension relationship among the deltoid and rotator cuff musculature. The scapular assistance test (SAT) is a physical examination manoeuvre aimed to detect patients in whom insufficient scapular upward rotation and posterior tilt contribute to the generation of shoulder symptoms. The SAT may, therefore, serve as an indication for the need of scapular focused intervention. Given the inconsistent results of scapular focused interventions among patients with SAIS, the purpose of this study is to assess the outcome of a scapular-focused intervention, particularly geared toward increasing scapular upward rotation, among patients with SAIS that exhibit a positive SAT as well.

Methods: Fifty patients with SAIS and a positive SAT referred to the "Meuhedet" outpatient physical therapy clinic in Ashdod will be recruited for this study. Following baseline assessment, patients will be randomized into 12 sessions over a 6-week period. The intervention group will receive manual therapy and an exercise program focused on increasing scapular upward rotation while the control group will receive manual therapy and an exercise program focused on scapular muscle an rotator cuff strengthening with no special emphasis on scapular upward rotation. Repeated measures analysis of covariance will be conducted to detect differences in pain intensity, shoulder -related disability and scapular upward rotation following the intervention
PROBLEM TO BE SOLVED: To obtain the subject composition having good skin persistence by compounding a medicine for dermal administration, an aliphatic polyhydric alcohol fatty acid ester, and butylene glycol, etc. SOLUTION: This composition for external use, having a pH of 4-9, when diluted into a 20-fold volume with purified water, comprises (A) a dermal administration medicine (preferably a compound having a mol.wt. of 150-550 and a melting point of 100-300 deg.C, e.g. a steroid agent) in an amount of 0.01-10 wt.% based on the preparation, (B) an aliphatic polyhydric alcohol fatty acid ester (preferably glycerol monoisostrearate, propylene glycol monoisostearate) in an amount of 0.1-25 wt.%, and (C) at least one of 1,3-butylene glycol or dipropylene glycol in an amount of 0.05-50 pts.wt. per pt.wt. of the component B.
BACKGROUND: Our recently developed Coronary Artery Tree description and Lesion EvaluaTion (CatLet) angiographic scoring system is unique in its description of the variability in the coronary anatomy, the degree of stenosis of a diseased coronary artery, and its subtended myocardial territory, and can be utilized to predict clinical outcomes for patients with acute myocardial infarction (AMI) presenting ≤12 h after symptom onset. The current study aimed to assess whether the Clinical CatLet score (CCS), as compared with CatLet score (CS), better predicted clinical outcomes for AMI patients presenting >12 h after symptom onset.
METHODS: CS was calculated in 1018 consecutive AMI patients enrolled in a retrospective registry. CCS was calculated by multiplying CS by the ACEF I score (age, creatinine, and left ventricular ejection fraction). Primary endpoint was major adverse cardiac events (MACEs) at 4-year-follow-up, a composite of cardiac death, myocardial infarction, and ischemia-driven revascularization.
RESULTS: Over a 4-year follow-up period, both scores were independent predictors of clinical outcomes after adjustment for a broad spectrum of risk factors. Areas-under-the-curve (AUCs) for CS and CCS were 0.72(0.68-0.75) and 0.75(0.71-0.78) for MACEs; 0.68(0.63-0.73) and 0.78(0.74-0.83) for all-cause death; 0.73(0.68-0.79) and 0.83(0.79-0.88) for cardiac death; and 0.69(0.64-0.73) and 0.75(0.7-0.79) for myocardial infarction; and 0.66(0.61-0.7) and 0.63(0.58-0.68) for revascularization, respectively. CCS performed better than CS in terms of the above-mentioned outcome predictions, as confirmed by the net reclassification and integrated discrimination indices.
CONCLUSIONS: CCS was better than CS to be able to risk-stratify long-term outcomes in AMI patients presenting >12 h after symptom onset. These findings have indicated that both anatomic and clinical variables should be considered in decision-making on management of patients with AMI presenting later.
BACKGROUND: There is an increasing prevalence of marijuana use in the general population yet clinical studies on marijuana's effect on surgical outcomes remain limited. Marijuana's effect on wound healing, venous thromboembolism (VTE) due to endothelial inflammation, and bleeding due to inhibited platelet function have been cited based on animal models but have not been evaluated clinically in patients undergoing microsurgical reconstruction.
METHODS: Retrospective chart review was performed on all patients who underwent abdominal-based free flap breast reconstruction in a single institute from August 2018 to December 2022. Patient self-reported marijuana use, demographics, total narcotic use during hospitalization converted to oral morphine milligram equivalent (MME), and 90-day complications were collected and compared.
RESULTS: A total of 162 patients were included and 13 patients (8.5%) had reported marijuana use on presurgical history. Marijuana users are more likely to be younger and report concurrent nicotine smoking. Marijuana users were also at a significantly elevated risk of developing symptomatic VTE (15 vs. 1%; odds ratio (OR) 13.4 [95% confidence interval (CI) 1.71-104.2]; p = 0.01) and marijuana use remained a significant risk factor with multivariate analysis. On postoperative 90-day complications, there was no increased risk of flap loss, reoperation, postoperative transfusion, or hematoma associated with marijuana use, and no significantly increased risk for overall donor or recipient site complications. Marijuana users required significantly more narcotics for pain control during hospitalization (100 ± 77 vs. 49 ± 45 MME; p = 0.0003), although they had similar lengths of stay, achievement of mobilization on post operative day (POD)1, and maximal pain scores.
CONCLUSION: Marijuana use increases the risks of postoperative VTE and increased postoperative narcotic requirements in patients who underwent abdominal-based free flap breast reconstruction. Future prospective cohort study is required to further understand marijuana-associated risks in microsurgical procedures.
The invention relates to medicine for treating dermatophytosis, in particular to a traditional Chinese medicine composition for treating dermatophytosis. The traditional Chinese medicine composition is prepared from Chinese herbal medicines. The traditional Chinese medicine composition is characterized by comprising, by weight, 20 parts of radix glycyrrhizae, 15 parts of radix angelicae dahuricae, 10 parts of herba taraxaci, 10 parts of rhizoma coptidis, 15 parts of radix sophorae flavescentis, 10 parts of radix astragali, 10 parts of radix angelicae sinensis, 25 parts of folium artemisiae argyi, 10 parts of pericarpium zanthoxyli, 4 parts of borneol, 15 parts of talcum, 15 parts of radix puerariae, 40 parts of herba houttuyniae and 20 parts of ciderage. According to present invention, the components of the traditional Chinese medicine composition are combined to complement each other, and the traditional Chinese medicine composition has the effects of counteracting toxic substances to expel stasis, killing worms to break accumulation, detoxifying to stop pains, dispersing wind heat and relieving itch. The traditional Chinese medicine composition achieves the synergistic effects of clearing heat to promote diuresis, warming yang to expel cold, detoxifying to kill worms, and relieving itch and stopping pain, thereby being capable of thoroughly treating dermatophytosis and preventing the relapse of dermatophytosis. The traditional Chinese medicine composition is economical and practical and has a simple formula, so that patients can operate by themselves.
1,139,869. Multilayer tablets. MOORE MEDICINAL PRODUCTS Ltd. 6 Jan., 1967 [6 Jan., 1966], No. 707/66. Heading A5B. A multilayer tablet comprises one layer formed from a mixture of a water-soluble drug and a pharmaceutically acceptable waterabsorbent substance which forms one or more stable hydrates (e.g. citric acid or its Na or K salt, or the Na or K salt of tartaric or phosphoric acid), but which is'-present in a fully or partially dehydrated form, the other layer or layers present not being water-absorbent. The other layer, or one of the other layers present may contain a water-insoluble drug. The acids or salts may initially be admixed with the drug in dehydrated form or they may be dehydrated by the action of heat during the preparation of the admixture for the tabletting operation. The example relates to a tablet with a core consisting of sucrose, methylephedrine hydrochloride, theophylline hydrate and magnesium stearate coated with a composition of gelatin, sucrose, talc, isoprenaline sulphate, antioxidants, citric acid and colouring agents. The tablets of the invention ensure that a water-soluble drug is retained in the desired location in the tablet. Enteric coatings may be used where desired.
The training, consisting of control group students will be trained with Powerpoint presentation, which will last 20-30 on average, will be given in accordance with the traditional education model. After the lesson, the questions of the students who have questions will be answered.
In this study, participants will receive gemcitabine and oxaliplatin, drugs that have been in use for a long time. Gemcitabine is a treatment that is an effective therapy currently available to patients with this type and stage of breast cancer. Frequently, in cancer therapy, combinations of drugs prove more effective as treatment than the same drugs used alone. The combination of gemcitabine and oxaliplatin has not been tested in patients with triple negative breast cancer. It is hoped that the addition of oxaliplatin may cause your tumor to stop growing or possible your tumor may shrink. This assessment will be basd on measuring changes in the size of your tumor.
Generalized Anxiety Disorder (GAD) is a common mental health disorder involving high levels of worry or tension. The symptoms are persistent and distressing and interfere with an individual's functioning and quality of life. Clinical evidence suggests that nutritional interventions, based on the Mediterranean diet and omega-3 fatty acid supplementation improve the symptoms of depression. To date, the effect of diet change interventions on anxiety symptoms has not been studied in trials involving people with diagnosed anxiety disorders. The primary objective of this study is to test the feasibility and acceptability of a dietary counselling and omega-3 fatty acid supplementation intervention delivered to adult women with GAD. The secondary objectives include measuring changes in anxiety symptom severity, measuring changes in quality of life, measuring changes in biomarkers and evaluation of the components of the program.

This study is a randomized, wait-list controlled pilot trial delivering a 12-week, dietary counselling intervention and omega-3 supplementation to 50 adult women with GAD. Participant will complete seven individual counselling sessions which include nutrition education, personalized recommendations, mindful eating techniques, motivational interviewing, and goal setting. They will be provided with recipes, instructional videos, and food items. Questionnaires and blood work will be completed at baseline, after the wait period (for those in the wait-list group) and after the intervention. The questionnaires will measure changes in anxiety symptom severity, quality of life, diet quality, mindful eating behaviours, and self-efficacy and lab tests will measure changes in biomarkers of nutritional status. All participants will be asked to complete a brief satisfaction survey concerning the participant's level of satisfaction with the program, the aspects which were helpful or unhelpful, and opportunities for improvement. A sub-sample will be recruited to participate in a brief focus group in order to obtain more detailed qualitative responses about the participant experience and participant satisfaction. Additional information will be collected to characterize study participants including demographic information, body mass index, physical activity and food security.

Results from this study will lay the foundation for future large-scale studies in this area and may provide preliminary evidence of the role of diet counselling and omega-3 supplementation in the management of GAD.